Trial Profile
A 12 week, randomized, double blind parallel group prospective dose ranging study of ZYH1 with an open pioglitazone arm to evaluate the efficacy on dyslipidemia in patients with Impaired Glucose tolerance Test.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2016
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary) ; Pioglitazone
- Indications Dyslipidaemias; Glucose intolerance
- Focus Therapeutic Use
- Sponsors Zydus Lifesciences
- 21 Mar 2013 Status changed from completed to discontinued as reported by Clinical Trials Registry - India record.
- 08 Sep 2010 Status changed from discontinued to completed as reported by Clinical Trials Registry - India record.
- 12 Mar 2010 New trial record